Trials / Active Not Recruiting
Active Not RecruitingNCT04777331
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 586 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prasinezumab | Prasinezumab will be administered as an IV infusion to participants Q4W. |
| DRUG | Placebo | Prasinezumab placebo will be administered to participants. |
Timeline
- Start date
- 2021-05-05
- Primary completion
- 2024-09-11
- Completion
- 2026-12-30
- First posted
- 2021-03-02
- Last updated
- 2026-03-09
- Results posted
- 2025-12-02
Locations
110 sites across 9 countries: United States, Austria, Canada, France, Italy, Luxembourg, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04777331. Inclusion in this directory is not an endorsement.